- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03896698
Feasibility Study of Transcranial Ultrasound Stimulation on Alzheimer's Disease Patients (TUS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to verify the feasibility of low intensity transcranial ultrasound stimulation (TUS) for patients with mild Alzheimer's disease (AD). As a secondary aim, the investigators will explore whether the TUS is associated with improvement in cognitive functioning six and forty-six weeks following the intervention.
Subjects will be randomly assigned to one of two experimental groups which with or without the TUS administration.
The investigators will study up to 20 subjects with mild AD. Initially, subjects will undergo a screening assessment with a study physician to determine medical and psychiatric history, establish AD diagnosis, and undergo a bold draw. Subjects that meet criteria and agree to participate in the study will undergo a follow-up visit. In the baseline measurement visit, participants will first undergo neuropsychological testing. Participants will be randomly assigned to one of two groups. Participants will then be administrated TUS treatment for six weeks. Subsequently, participants will undergo a series of neuropsychological test. A final follow-up assessment will be administered at forty-six weeks.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jong-Ling Fuh, M.D.
- Phone Number: 886-2-28762522
- Email: jlfuh@vghtpe.gov.tw
Study Contact Backup
- Name: Feng-Yi Yang, Ph.D.
- Phone Number: 886-2-28267281
- Email: fyyang@ym.edu.tw
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Jong-Ling Fuh, M.D.
-
Principal Investigator:
- Jong-Li Fuh, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 55 and 90 years old
- Weight greater than 50 kg
- Male or Female
- Good understanding of written and verbal Chinese
- Geriatric Depression Scale (GDS) score of < 8
- Mild AD patients (Mini-Mental State Examination (MMSE) 20-26)
- Probable AD consistent with NIA/AA criteria
- The blood flow of bilateral middle cerebral artery M1 can be detected by Transcranial Color Doppler (TCD)
- Caregiver spending at least 10 hours per week with the patient
- Agreement to obey the rules of this study
- Use of cholinesterase inhibitors for AD (Aricept, Namenda, etc.) will be allowed as long as the participant has been on a stable dose for at least six months
- Does have a reliable caregiver in frequent contact with the patient and can accompany the patient to the clinic and treatment
Exclusion Criteria:
- Evidence of any other major neurologic or other physical illness that could produce cognitive deterioration, except for mild cognitive impairment (MCI) and any history of stroke or diabetes
- History of myocardial infarction within the previous year or unstable cardiac disease
- Any contraindications to MRI scanning such as metallic implants, claustrophibia or too large for MRI scanner
- History of liver disease or severely impaired renal function
- The blood flow of either unilateral middle cerebral artery M1 can't be detected by Transcranial Color Doppler (TCD)
- Major psychiatric disorders, such as bipolar disorder or schizophrenia, or persons with current untreated major depression
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TUS treatment
AD patients with TUS treatment
|
TUS activate the brain cells
|
No Intervention: Non-TUS treatment
AD patients with Non-TUS treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device and procedure related adverse events recording
Time Frame: up to 46 weeks after treatment
|
Rate of adverse events following each treatment through end of study Clinical and MRI evaluation
|
up to 46 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)
Time Frame: Change from baseline at 7, 12, 24, and 52 week
|
ADAS was designed to measure the severity of the most important symptoms of Alzheimer's disease (AD).
Its subscale ADAS-cog is the most popular cognitive testing instrument used in clinical trials of nootropics.
It consists of 11 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD.
The test administrator adds up points for the errors in each task of the ADAS-Cog for a total score.
Total scores range from 0-70.
The greater the dysfunction, the greater the score.
|
Change from baseline at 7, 12, 24, and 52 week
|
Clinical Dementia Rating (CDR)
Time Frame: Change from baseline at 12 and 52 week
|
The Clinical Dementia Rating or CDR is a numeric scale used to quantify the severity of symptoms of dementia (i.e. its 'stage').
Using a structured-interview protocol, qualified health professional assesses a patient's cognitive and functional performance in six areas: memory, orientation, judgment & problem solving, community affairs, home & hobbies, and personal care.
Scores in each of these are combined to obtain a composite score ranging from 0 through 3, with 0 meaning of no symptoms, 0.5 very mild dementia, 1 mild dementia, 2 moderate dementia and 3 severe dementia.
|
Change from baseline at 12 and 52 week
|
Neuropsychiatric Inventory Questionnaire (NPI-Q)
Time Frame: Change from baseline at 12 and 52 week
|
NPI-Q is a carer-based tool that assesses the possible presence of 12 symptoms in dementia cases, including delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviors, night-time behavioral disturbances and appetite/eating disturbances.
The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress).
The total scores of severity and caregiver stress are summed of each 12 items separately, with with higher scores indicating a greater number of neuropsychiatric symptoms or distress.
|
Change from baseline at 12 and 52 week
|
Transcranial Doppler (TCD)
Time Frame: Changes in blood flow from baseline at 12 and 52 week
|
Cerebral blood flow evaluation
|
Changes in blood flow from baseline at 12 and 52 week
|
Magnetic Resonance Image (MRI)
Time Frame: Change from baseline at 12 and 52 week
|
Brain observation
|
Change from baseline at 12 and 52 week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Feng-Yi Yang, Ph.D., National Yang Ming University
Publications and helpful links
General Publications
- Chen TT, Lan TH, Yang FY. Low-Intensity Pulsed Ultrasound Attenuates LPS-Induced Neuroinflammation and Memory Impairment by Modulation of TLR4/NF-kappaB Signaling and CREB/BDNF Expression. Cereb Cortex. 2019 Apr 1;29(4):1430-1438. doi: 10.1093/cercor/bhy039.
- Chen CM, Wu CT, Yang TH, Liu SH, Yang FY. Preventive Effect of Low Intensity Pulsed Ultrasound against Experimental Cerebral Ischemia/Reperfusion Injury via Apoptosis Reduction and Brain-derived Neurotrophic Factor Induction. Sci Rep. 2018 Apr 3;8(1):5568. doi: 10.1038/s41598-018-23929-8.
- Chen SF, Su WS, Wu CH, Lan TH, Yang FY. Transcranial Ultrasound Stimulation Improves Long-Term Functional Outcomes and Protects Against Brain Damage in Traumatic Brain Injury. Mol Neurobiol. 2018 Aug;55(8):7079-7089. doi: 10.1007/s12035-018-0897-z. Epub 2018 Jan 30.
- Su WS, Wu CH, Chen SF, Yang FY. Low-intensity pulsed ultrasound improves behavioral and histological outcomes after experimental traumatic brain injury. Sci Rep. 2017 Nov 14;7(1):15524. doi: 10.1038/s41598-017-15916-2.
- Su WS, Wu CH, Chen SF, Yang FY. Transcranial ultrasound stimulation promotes brain-derived neurotrophic factor and reduces apoptosis in a mouse model of traumatic brain injury. Brain Stimul. 2017 Nov-Dec;10(6):1032-1041. doi: 10.1016/j.brs.2017.09.003. Epub 2017 Sep 7.
- Huang SL, Chang CW, Lee YH, Yang FY. Protective Effect of Low-Intensity Pulsed Ultrasound on Memory Impairment and Brain Damage in a Rat Model of Vascular Dementia. Radiology. 2017 Jan;282(1):113-122. doi: 10.1148/radiol.2016160095. Epub 2016 Jul 11.
- Liu SH, Lai YL, Chen BL, Yang FY. Ultrasound Enhances the Expression of Brain-Derived Neurotrophic Factor in Astrocyte Through Activation of TrkB-Akt and Calcium-CaMK Signaling Pathways. Cereb Cortex. 2017 Jun 1;27(6):3152-3160. doi: 10.1093/cercor/bhw169.
- Su WS, Tsai ML, Huang SL, Liu SH, Yang FY. Controllable permeability of blood-brain barrier and reduced brain injury through low-intensity pulsed ultrasound stimulation. Oncotarget. 2015 Dec 8;6(39):42290-9. doi: 10.18632/oncotarget.5978.
- Lin WT, Chen RC, Lu WW, Liu SH, Yang FY. Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. Sci Rep. 2015 Apr 15;5:9671. doi: 10.1038/srep09671.
- Yang FY, Lu WW, Lin WT, Chang CW, Huang SL. Enhancement of Neurotrophic Factors in Astrocyte for Neuroprotective Effects in Brain Disorders Using Low-intensity Pulsed Ultrasound Stimulation. Brain Stimul. 2015 May-Jun;8(3):465-73. doi: 10.1016/j.brs.2014.11.017. Epub 2014 Dec 4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TUS01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Transcranial Ultrasound Stimulation
-
First Affiliated Hospital of Zhejiang UniversityRecruiting
-
Spaulding Rehabilitation HospitalHighland Instruments, Inc.Active, not recruitingOsteoarthritis | Chronic PainUnited States
-
University of VirginiaUnknownPain, Acute | Pain, Chronic | Pain, ExperimentalUnited States
-
Spaulding Rehabilitation HospitalNational Institute of Neurological Disorders and Stroke (NINDS); Highland Instruments...Completed
-
Spaulding Rehabilitation HospitalHighland Instruments, Inc.RecruitingChronic Pain | Carpal Tunnel SyndromeUnited States
-
Spaulding Rehabilitation HospitalHighland Instruments, Inc.CompletedOsteoarthritis | Chronic PainUnited States
-
Shanghai Mental Health CenterNot yet recruitingNegative Symptoms of SchizophreniaChina
-
Cheng-Hsin General HospitalRecruitingHemiplegia | Intracerebral HemorrhageTaiwan
-
Xuanwu Hospital, BeijingNot yet recruiting
-
University of VirginiaUnknown